Livzon Pharmaceutical details A-share repurchases for cancellation

Livzon Pharmaceutical Group Inc. (HKEX: 01513) reported no changes in its H-share capital, maintaining 299,807,117 ordinary H-shares as of September 2, 2025. The company confirmed that all money due for share issues or transfers has been received and all listing preconditions and legal requirements have been met.

The disclosure primarily highlights a series of A-share repurchases, with 604,293,313 ordinary A-shares outstanding at the opening balance on September 1, 2025. The company has actively repurchased its A-shares for cancellation, with the latest repurchase of 71,400 A-shares occurring on September 2, 2025, at a volume-weighted average price of RMB41.71, totaling RMB2,977,770.

This recent repurchase brings the total number of A-shares repurchased for cancellation to 71,400. Other repurchases detailed in the report include 48,600 A-shares on September 1, 2025, at RMB41.58, and various repurchases throughout July, August, and from December 2024 through April 2025, at prices ranging from RMB34.00 to RMB41.99. These repurchased shares are pending cancellation and are reflected in the "Shares redeemed or repurchased for cancellation but not yet cancelled" section, indicating the company's ongoing capital management strategy.